Evercore ISI sees increased risk to Moderna RSV estimates

Evercore ISI analyst Cory Kasimov says shares of all three respiratory syncytial virus sponsors, GSK (GSK), Pfizer (PFE) and Moderna (MRNA), were pressured yesterday by the language of the Advisory Committee on Immunization Practices vote, “which may suggest the RSV market could be far more restricted than previously thought.” The recommendation language for a single “lifetime” dose is a “significant negative surprise,” the analyst tells investors in a research note. The firm adds that while Moderna’s presentation shows 50% vaccine efficacy at 18 months, the ACIP presentation cited less than 40%. Evercore now sees increased risk to the company’s RSV estimates and keeps an In-Line rating on the shares with a $120 price target.